Allred Capital Management LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Allred Capital Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,998 shares of the company’s stock after selling 240 shares during the quarter. Johnson & Johnson accounts for approximately 1.7% of Allred Capital Management LLC’s investment portfolio, making the stock its 11th biggest holding. Allred Capital Management LLC’s holdings in Johnson & Johnson were worth $4,338,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. IFS Advisors LLC increased its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $33,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on JNJ. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Bank of America reduced their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Raymond James reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $171.72.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 2.3 %

NYSE JNJ opened at $157.42 on Friday. The firm has a market cap of $379.37 billion, a PE ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm’s fifty day moving average is $159.47 and its two-hundred day moving average is $155.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.